World-leading cellular therapy company views 'Gateway to China' as
strategic to global expansion plans
HONG KONG, Nov. 8, 2011 /PRNewswire-Asia/ --
Laboratoires Dom AVMM (Suisse) Inc (Lab Dom) -- a world-leading
regenerative medicine and cellular therapy company specialising in
precursor stem cell, placental extract, organ-specific and
botanical cell products -- is launching its innovative '68 Days of
Change' consumer cellular therapy challenge at Hong Kong's
'Cosmoprof Asia 2011' aesthetic exhibition being held from 9-11
November 2011.
The consumer campaign is aimed at encouraging
exhibition attendees to experience 'Change, with Lab Dom' by
signing up to win 68 days worth of the company's premium cellular
therapy brand -- MFIII of Switzerland's Nano Cell Extracts for Skin
-- and posting a daily photo update of the change to the company's
dedicated website www.changewithlabdom.com to share the
results.
"A new era is dawning in the regenerative medicine
industry, and Lab Dom is a well-respected pioneer at the forefront
of that change," explained Michelle Wong, co-founder of Lab
Dom.
"We are in the business of providing the opportunity
for change for humankind, and an opportunity to increase the
quality of life itself. We believe our '68 Days of Change'
challenge will open the experience of our award-winning MFIII Nano
Cell Extracts to the vibrant and rapidly expanding Chinese
market."
Lab Dom's '68 Days of Change' consumer incentive
program will be opened to global participants at various
international exhibitions in the coming months, and forms part of
the company's dynamic new stakeholder campaign 'Change, with Lab
Dom'.
"Our new stakeholder campaign is aimed at servicing
stakeholders and customers around the globe at a world's best
practice level, as we embark on ambitious global expansion plans,"
said Mike Chan, co-founder of Lab Dom.
"This will incorporate an innovative distribution
model and channel activation program, as well as new corporate
branding, which will be officially unveiled in Las Vegas in
December this year."
Hong Kong is perceived as a vital gateway to China
by the company, as part of its intention to capitalise on its
existing leading presence in the Asia-Pacific region and expand
into China, the European Union, North and South America as well as
the Middle East.
According to a study by the Canadian-based
McLaughlin-Rotman Centre for Global Health (MRC), published by the
UK journal Regenerative Medicine( http://www.futuremedicine.com/toc/rme/5/1 ),
the Chinese government is currently investing heavily in
regenerative medicine research with the aim of becoming a world
leader in the field. The country's gross domestic expenditure on
research and development in the field has grown from USD 5.9
billion in 1996 to USD 44 billion today. (Note
1)
"With China expecting to play a future pivotal role
in stem cell research and development, it is crucial for us to
establish a key presence in this important emerging market. Our
participation at this exhibition is firmly aimed at opening the
opportunity for preferred partners and associates in the region to
join us, share the bounty of our science and grow with our new
business," continued Mike Chan.
Hong Kong's 'Cosmoprof Asia 2011' marks the fourth
international event, in a series of six, that Lab Dom is
participating in this year to create awareness of its new 'Change,
with Lab Dom' stakeholder campaign. Lab Dom recently successfully
introduced the campaign to the South-East Asian market, following
its launch in Paris, France in September this year and the
company's first Middle East regenerative medicine conference held
in Beirut, Lebanon in October.
For more information visit www.labdom.com and
www.changewithlabdom.com
Note:
1. 'China a rising star in regenerative medicine', 9
January 2010,
www.gizmag.com/china-a-rising-star-in-regenerative-medicine/13806
About Lab Dom
Laboratoires Dom AVMM (Suisse) Inc., (LabDom) is a
Swiss held and globally headquartered regenerative medicine and
cellular therapy company, with regional Asia-Pacific headquarters
in Kota Kinabalu, Malaysia.
Founded in 1998 by entrepreneurial husband and wife
team, Mike Chan and Michelle Wong, LabDom is a world-leader in
precursor stem cell, placenta extract, organ-specific and botanical
cell product manufacturing and distribution, providing rejuvenation
and revitalisation therapies to combat aging and chronic
degenerative diseases.
With state-of-the-art laboratories and highly
professional medical staff based in Switzerland, as well as the
European Union and Asia-Pacific, Lab Dom is committed to innovative
research and development in the rapidly expanding fields of
regenerative medicine and anti-aging cellular therapy
fields.
www.labdom.com
About MFIII
MFIII of Switzerland is a world-renowned anti-aging
cellular therapy brand, manufactured and distributed by its parent
company Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) -- a world
leader in the regenerative medicine industry and cellular therapy
field.
Launched to market in 2003, MFIII of Switzerland
excels in rejuvenation and revitalisation therapy products using
placenta, organ-specific and botanical extracts to combat chronic
degenerative diseases and anti-aging.
Signature MFIII cellular product ranges received
awards at Switzerland's 2011 International Exhibition of Inventions
of Geneva Gold Medals for Innovation -- the 'Innovation in
Anti-Aging Formulation Technologies' for MFIII PE Advance Formula
Softgels and the 'Innovations in Regenerative Medicine' for MFIII
Nano Cell Extracts.
About FCTI
Fetal Cell Technologies International Inc., (FCTI)
is one of the world's largest manufacturers and distributors of
precursor stem cellular therapy products, held by its parent
company Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) -- a world
leader in the regenerative medicine industry and cellular therapy
fields.
Standing at the frontier of biotechnology in the
field of modern integrative therapies and regenerative medicine
since 2006, FCTI's precursor stem cellular therapy product
portfolio is aimed at certified medical
practitioners.
This product range, which includes the
Eco-Ultrafiltrates (EUF) and ASI Therapy brands, has yielded
unprecedented results in the treatment of diseases deemed
previously untreatable by conventional therapies such as Downs
Syndrome, autism, cerebral palsy, diabetes, Parkinson's Disease and
chronic arthritis.
FCTI's premium practitioner product,
Eco-Ultrafiltrates (EUF) received the 'Bio-Regenerative Medicine'
award at the prestigious 2011 International Exhibition of
Inventions of Geneva Gold Medals for Innovation, held in
Switzerland.
For media inquiries contact:
Andrew Tham
Message Manager
Tel: +60-16-810-5490
Lab Dom
email: [email protected]
SOURCE: Laboratoires Dom AVMM (Suisse)
Inc.